연구동향 분석
박사

개방형 혁신 활동이 기술사업화 성과에 미치는 영향 : 국내 바이오·제약 산업을 중심으로

강지민 2013년

논문상세정보
인용/피인용
' 개방형 혁신 활동이 기술사업화 성과에 미치는 영향 : 국내 바이오·제약 산업을 중심으로' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 일반 경영
  • 개방형 혁신
  • 기술사업화 성과
  • 기술혁신
  • 바이오·제약 산업
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
1,163 2

0.0%

' 개방형 혁신 활동이 기술사업화 성과에 미치는 영향 : 국내 바이오·제약 산업을 중심으로' 의 참고문헌

  • 한의기술 사업화 과정의 재무적 특성에관한 연구
    [2010]
  • 한국 제조업의 개방형 기술혁신 현황과 효과 분석
  • 박사
    한국 기술사업화의 실태와 발전과제:공공기술을 중심으로
    박종복 한국 기술사업화의 실태와 발전과제 - 공공기술을 중심으로 [1999]
  • 제약분야의 에버그리닝 특허전략과 FTA 연구
    정윤택 [2011]
  • 정보통신 기술의 상용화 성공요인 분석
    이영덕 [2004]
  • 우리나라 중소기업의 기술협력형태 및 성과영향요인에 관한 연구
    정진우 [2005]
  • 우리나라 개방형 혁신활동의 영향요인에 관한 실증분석 연구
  • 연구개발된 정보통신 기술의 효율적 상용화 지원 방안 연구
  • 바이오인포매틱스 제품의 상용화 : 외부통합의 중요성
  • 기술이전성과와 결정요인에 관한 연구
    안성조 이관률 이성근 한국지역개발학회지 [2005]
  • 공공기관의 기술이전 활성화 전략
    이윤준 [2008]
  • 개방형 혁신활동 및 성과의 영향요인에 관한 실증연구
    안치수 [2010]
  • 개방형 혁신이 혁신성과에 기여하는가? : 한국 중소기업으 로부터의 실증적 증거
    권영관 개방형 혁신이 혁신성과에 기여하는가? : 한국 중소기업으로부터의실증적 증거 [2010]
  • 개방형 혁신은 새로운 혁신 방법론인가?: Chesbrough의 개방형 혁신이론에 대한 비판적 평가
    김석관 [2009]
  • Winning at New Products : Accelerating theProcess from Idea to Launch (3rd ed)
  • Why companies should have open business models
    Chesbrough [2007]
  • Who cooperates on R&D?
    Fritsch R.Lukas Who cooperates on R&D? [2001]
  • Who co-operates for innovation, and why: An empirical analysis
    Tether Who co-operates for innovation [2002]
  • The role of users in innovation inthe pharmaceutical industry
    Boon Smits [2008]
  • The role of technology in theshift towards open innovation: the case of Procter & Gamble
  • The relationship between a firm's level of technological innovativeness and its pattern of partnership agreements
    Dutta Weiss The relationship between a firm's level oftechnological innovativeness and its pattern of partnership agreements [1997]
  • The product market and the market for ideas: commercialization strategies for technology entrepreneurs
    Gans Stern The product market and the market forideas: commercialization strategies for technology entrepreneurs [2003]
  • The outsourcing of R&D through acquisitions in the pharmaceutical industry
    Higgins Rodriguez The outsourcing of R&D throughacquisitions in the pharmaceutical industry [2006]
  • The open innovation journey: How firms dynamically implement the emerging innovation management paradigm
  • The future of openinnovation
  • The ex ante assessment of knowledgespillover: Government R&D Policy, Economic Incentives and Private FirmBehavior
    Feldman Kelly The ex ante assessment of knowledgespillover: Government R&D Policy [2006]
  • The effects of government financial support onbusiness innovation in South Korea
    Kim Lee [2011]
  • The determinants of the choiceof innovation source for Chinese firms
  • The determinants of commercialization strategy:Idiosyncrasies in British and German biotechnology
    Haeussler [2010]
  • The commercialization of government-sponsoredtechnologies: canadian evidence
    Supapol [1990]
  • The commercialization of federally sponsored technologicalinnovations
    Ettlie [1982]
  • The Influence of Business Strategies On Technological Network Activities
  • Technology commercializaton in International TechnologyTransfer
    KoKubu [2001]
  • Technology commercialization, incubator and venture capital,and new venture performance
    Chen Technology commercialization [2009]
  • Technological cooperative agreements andfirm's R&D intensity. A note on causality relations
  • Strategic Considerations for Innovation andCommercialization in the US Biotechnology Sector
    Bagchi-Sen [2007]
  • Strategic Alliance Structuring: A Game Theoretic andTransaction Cost Examination of Interfirm Cooperation
  • Stage-Gate System for New Product Success
    Cooper ( [2003]
  • Sources of information as determinants of novelty of innovation in manufacturing firms: Evidence from the 1999 statistics Canada innovation survey
    Amara Landry Sources of information as determinants of noveltyof innovation in manufacturing firms: evidence from the 1999 statisticsCanada innovation survey [2005]
  • Sources of capabilities, integration and technology commercialization
    Nielsen Zahra Sources of capabilities [2002]
  • Reflections on “Profiting from innovation
    Teece [2006]
  • Rationales for government interventionin the commercialization of new technology
  • Public/private technologypartnerships: evaluating SBIR-supported research
  • Prospects for productivity
  • Profiting from Technological Innovation
    Teece Profiting from technological innovation [1986]
  • Outbound Open Innovation and itsEffectonFirm Performance: Examining Environmental Influences
    Lichtenthaler Outbound open innovation and its effect on firmperformance: examining environmental influences [2009]
  • Organizational modes for open innovation in the bio-pharmaceutical industry:An exploratory analysis
  • Opening up the innovation process: towards an agenda
    Gassmann [2006]
  • Open-source software development and distributedinnovation
  • Open innovation: state of the art and futureperspectives
    Huizingh [2011]
  • Open innovation in practice: An analysis of strategic approaches to technology transactions
    Lichtenthaler Open innovation in practice: an analysis of strategicapproaches to technology transactions [2008]
  • Open innovation in SMEs?an intermediated network model
  • Open innovation in SMEs: trends, motives and management challenges
    Vanhaverbeke de Jong de Rochemont van de Vrande Open innovation in SMEs: trends [2009]
  • Open innovation : the new imperative for creating and profiting from technology
    Chesbrough, Henry William Open Innovation: the new imperative for creatingand profiting from technology [2006]
  • Open for innovation: The role of openness in explaining innovation performance among U.K. manufacturing firms
    Laursen Salter Open for innovation: the role of openness inexplaining innovation performance among U.K. manufacturing firms [2006]
  • Open R&D and open innovation: exploring the phenomenon
    Enkel H.Chesbrough O.Gassmann Open R&D and openinnovation: exploring the phenomenon [2009]
  • Open Innovation and Strategy
  • Open Business Model: How to thrive in the newinnovation landscapee
    Chesbrough [2006]
  • No Business is an Island: The networkconcept of business strategy
  • Modes of cooperative R&D commercializationby start-ups
  • Licensing as a commercialisation strategy for new technology-based firms
    Dowling Kollmer Licensing as a commercialisation strategyfor new technology-based firms [2004]
  • LG화학의 개방형 혁신 도입과정과 우리나라 기업에의 적용에 관한고찰, 「기술혁신연구
    양희승 LG화학의 개방형 혁신 도입과정과 우리나라 기업에의 적용에 관한고찰 [2009]
  • Knowledge sources, patent protection, and commercializationof pharmaceutical innovations
    Sternitzke Knowledge sources [2010]
  • Is open innovation the way forward for bigpharma
  • Investigate the adoption of openinnovation I the bio-pharmaceutical industry
  • Government as entrepreneur: evaluating thecommercialization success of SBIR project
    Link Scott [2010]
  • Free revealing and the private-collective model for innovation incentives
  • Externally Commercializing technology assets: Anexamination of different process stages
  • Effect of R&D and patents onfinancial performance of Korean venture firms
    Kim Shon [2010]
  • Dynamic capabilities and strategic management
    Shuen Teece Dynamic capabilities andstrategic management [1997]
  • Cooperative R&D and firm performance
  • Connect and develop: inside Procter&Gamble’snew model for innovation
    Huston [2006]
  • Complementary Assets, strategicalliances, and the incumbent's advantage: An empiricalstudy of industry and firm effects in the bio-pharmaceuticalindustry
    Rothaermel Complementary assets [2001]
  • Community, joining, andspecialization in open source software innovation
    Von Krogh G. Community [2003]
  • Commercializing new technologies : getting from mind to market
  • Commercialization strategies of young biotechnology firms: An empirical analysis of the US industry
    Kasch S [2008]
  • Challenges of open innovation: the paradox of firm investment in open-source software
  • Can the pharmaceutical industry reduce attritionrates?
    Kola [2004]
  • Can open-source R&D reinvigorate drug research?
    Munos [2006]
  • Broadening thescope of open innovation: past research, current state and futuredirections
    Gassmann Van de Vr Broadening thescope of open innovation: past research [2010]
  • Antecedents of cooperative commercialization strategies of nanotechnology firms
    Fiedler [2010]